Mariapaola Cucinotta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariapaola Cucinotta has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
A. Crucitti
Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria n. 1, 98125 Messina, Italy
1 shared publication- Alessandra Bitto
Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy
1 shared publication Alfredo Campennì
Department of Biomedical Sciences and of Morphological and Functional Images, Nuclear Medicine Unit, University of Messina, 98125 Messina, Italy
1 shared publicationAlireza Mojtahedi
Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
1 shared publication- Angelina Cistaro
Nuclear Medicine Department, Salus Alliance Medical, 16128 Genoa, Italy
1 shared publication - Antonino Catalano
Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 January 2017
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 8416763
Oxidative Stress: Harms and Benefits for Human Health
Oxidative stress is a phenomenon caused by an imbalance between production and accumulation of oxygen reactive species (ROS) in cells and tissues and the ability of a biological system to detoxify these reactive products. ROS can play, and in fact they do it, several physiological roles (i.e., cell signaling), and they are normally generated as by‐products of oxygen metabolism; despite this, environmental stressors (i.e., UV, ionizing radiations, pollutants, and heavy metals) and xenobiotics (i.e., antiblastic drugs) contribute to greatly increase ROS production, therefore causing the imbalance that leads to cell and tissue damage (oxidative stress). Several antioxidants have been exploited in recent years for their actual or supposed beneficial effect against oxidative stress, such as vitamin E, flavonoids, and polyphenols. While we tend to describe oxidative stress just as harmful for human body, it is true as well that it is exploited as a therapeutic approach to treat clinical conditions such as cancer, with a certain degree of clinical success. In this review, we will describe the most recent findings in the oxidative stress field, highlighting both its bad and good sides for human health.
- 1 January 2017
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 8416763
Top Cited PapersOpen AccessOxidative Stress: Harms and Benefits for Human Health
Oxidative stress is a phenomenon caused by an imbalance between production and accumulation of oxygen reactive species (ROS) in cells and tissues and the ability of a biological system to detoxify these reactive products. ROS can play, and in fact they do it, several physiological roles (i.e., cell signaling), and they are normally generated as by‐products of oxygen metabolism; despite this, environmental stressors (i.e., UV, ionizing radiations, pollutants, and heavy metals) and xenobiotics (i.e., antiblastic drugs) contribute to greatly increase ROS production, therefore causing the imbalance that leads to cell and tissue damage (oxidative stress). Several antioxidants have been exploited in recent years for their actual or supposed beneficial effect against oxidative stress, such as vitamin E, flavonoids, and polyphenols. While we tend to describe oxidative stress just as harmful for human body, it is true as well that it is exploited as a therapeutic approach to treat clinical conditions such as cancer, with a certain degree of clinical success. In this review, we will describe the most recent findings in the oxidative stress field, highlighting both its bad and good sides for human health.
- 12 March 2014
- Published by Elsevier in European Geriatric Medicine
- Vol. 5 (4) , 242-245
Serum levels of Apelin-36 are decreased in older hospitalized patients with heart failure
- 12 March 2014
- Published by Elsevier in European Geriatric Medicine
- Vol. 5 (4) , 242-245
Serum levels of Apelin-36 are decreased in older hospitalized patients with heart failure
- Open Access
- 1 January 2013
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 910957
Is %ΔSUVmax a Useful Indicator of Survival in Patients with Advanced Nonsmall‐Cell Lung Cancer?
Purpose. To investigate the impact of the maximum standardized uptake value (SUVmax), size of primary lung lesion, and %ΔSUVmax on outcome (overall survival (OS) and 2‐year disease‐free survival (2‐year DFS)) of patients with advanced nonsmall‐cell lung cancer (NSCLC). Materials and Methods. 86 stage III‐IV NSCLC patients underwent 18 F‐FDGPET/CT, before and after chemotherapy, and were classified into subgroups according to the response criteria of the European Organization for Research and Treatment of Cancer. SUVmax values and tumor size with the best prognostic significance were searched. Correlation between the SUVmax value and the initial response to therapy (best response) and the relationship between %ΔSUVmax and OS were assessed. Results. In patients in PD (20/86), the average pretreatment SUVmax was 11.8 ± 5.23, and the mean size of the primary lesion was 43.35 mm ± 16.63. In SD, PR, and CR patients (66/86), the average pretreatment SUVmax was 12.7 ± 8.05, and the mean size of the primary lesion was 41.6 mm ± 21.15. Correlation was identified only for %ΔSUVmax; patients with PD (ΔSUVmax > +25%) showed a worse OS than patients with ΔSUVmax < +25% (CR, PR, and SD) (P = 0.0235). Conclusions. In stage III‐IV NSCLC, among the assessed factors, only %ΔSUVmax may be considered as a useful prognostic factor.
- 1 January 2013
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 910957
Open AccessIs %ΔSUVmax a Useful Indicator of Survival in Patients with Advanced Nonsmall‐Cell Lung Cancer?
Purpose. To investigate the impact of the maximum standardized uptake value (SUVmax), size of primary lung lesion, and %ΔSUVmax on outcome (overall survival (OS) and 2‐year disease‐free survival (2‐year DFS)) of patients with advanced nonsmall‐cell lung cancer (NSCLC). Materials and Methods. 86 stage III‐IV NSCLC patients underwent 18 F‐FDGPET/CT, before and after chemotherapy, and were classified into subgroups according to the response criteria of the European Organization for Research and Treatment of Cancer. SUVmax values and tumor size with the best prognostic significance were searched. Correlation between the SUVmax value and the initial response to therapy (best response) and the relationship between %ΔSUVmax and OS were assessed. Results. In patients in PD (20/86), the average pretreatment SUVmax was 11.8 ± 5.23, and the mean size of the primary lesion was 43.35 mm ± 16.63. In SD, PR, and CR patients (66/86), the average pretreatment SUVmax was 12.7 ± 8.05, and the mean size of the primary lesion was 41.6 mm ± 21.15. Correlation was identified only for %ΔSUVmax; patients with PD (ΔSUVmax > +25%) showed a worse OS than patients with ΔSUVmax < +25% (CR, PR, and SD) (P = 0.0235). Conclusions. In stage III‐IV NSCLC, among the assessed factors, only %ΔSUVmax may be considered as a useful prognostic factor.